Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

    NEXT STORY
    Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
    PREV STORY
    10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients

    EDISON, NJ, April 20, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

    First FDA-Approved Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease ...

    author_avatar
    NASDAQ Market News

    Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

    author_avatar
    NASDAQ Market News